Differential contextual responses of normal human breast epithelium to ionizing radiation in a mouse xenograft model

Cancer Research

Volumn 70, Issue 23, 2010, Pages 9808-9815

  Coates, Philip J ^a   Appleyard, M Virginia C L ^a   Murray, Karen ^a   Ackland, Caroline ^a   Gardner, June ^a   Brown, Douglas C ^a   Adamson, Dougal J A ^a   Jordan, Lee B ^a   Purdie, Colin A ^a   Munro, Alastair J ^a   Wright, Eric G ^a   Dewar, John A ^a   Thompson, Alastair M ^a,b  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 1A; HISTONE H2AX; PROTEIN P21; PROTEIN P53;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BASAL CELL; BREAST; BREAST CARCINOMA; BREAST DUCT; BREAST EPITHELIUM; CLINICAL ARTICLE; CONTROLLED STUDY; DNA DAMAGE; DOSE RESPONSE; EPITHELIUM BASAL CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; IONIZING RADIATION; IRRADIATION; MOUSE; NONHUMAN; NORMAL HUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RADIATION DOSE; RADIATION RESPONSE; STROMA CELL; TISSUE PRESERVATION; XENOGRAFT;

ANIMALS; APOPTOSIS; BREAST; CASPASE 3; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DOSE-RESPONSE RELATIONSHIP, RADIATION; ENZYME ACTIVATION; EPITHELIAL CELLS; EPITHELIUM; FEMALE; HISTONES; HUMANS; IMMUNOHISTOCHEMISTRY; MICE; MICE, SCID; MODELS, ANIMAL; PHOSPHORYLATION; SERINE; TIME FACTORS; TRANSPLANTATION, HETEROLOGOUS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 78649962450     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-10-1118     Document Type: Article

References (54)

1. Stebbing J, Delaney G, Thompson AM. Clinical Evidence Handbook; Breast Cancer (Non-metastatic). London, UK: BMJ Publishing Group; 2008.
2. Bentzen SM, Skoczylas JZ, Overgaard M, Overgaard J. Radiotherapy-related lung fibrosis enhanced by tamoxifen. J Natl Cancer Inst 1996;88:918-22. (Pubitemid 26230643)
3. Vicini FA, Kestin L, Chen P, Benitez P, Goldstein NS, Martinez A. Limited-field radiation therapy in the management of early-stage breast cancer. J Natl Cancer Inst 2003;95:1205-10. (Pubitemid 37069550)
4. Vaidya JS, Joseph DJ, Tobias JS, Bulsara M, Wenz F, Saunders C, et al. Targeted intraoperative radiotherapy versus whole breast radiotherapy for breast cancer (TARGIT-A trial): an international, prospective, randomised, non-inferiority phase 3 trial. Lancet 2010;376:91-102.
5. Vaidya JS, Baum M, Tobias JS, D'Souza DP, Naidu SV, Morgan S, et al. Targeted intra-operative radiotherapy (Targit): an innovative method of treatment for early breast cancer. Ann Oncol 2001;12:1075-80. (Pubitemid 32834487)
6. Hiley C, Tutt A, Torres M, Palmieri C. Adjuvant radiotherapy for breast cancer. BMJ 2009;338:4-5.
7. Barnett GC, West CM, Dunning AM, Elliott RM, Coles CE, Pharoah PD, et al. Normal tissue reactions to radiotherapy: towards tailoring treatment dose by genotype. Nat Rev Cancer 2009;9:134-42.
8. Alsner J, Andreassen CN, Overgaard J. Genetic markers for prediction of normal tissue toxicity after radiotherapy. Semin Radiat Oncol 2008;18:126-35. (Pubitemid 351296451)
9. Appella E, Anderson CW. Post-translational modifications and activation of p53 by genotoxic stresses. Eur J Biochem 2001;268:2764-72. (Pubitemid 32862957)
10. Staples O, Lain S, Ziyaie D, Thompson AM p53 and breast cancer. In: Walker RA, Thompson AM, editors. Prognostic and Predictive Factors in Breast Cancer. London, UK: Informa Health Care; 2008, p. 148-67.
11. Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature 2000;408:307-10.
12. Green DR, Chipuk JE. p53 and metabolism: inside the TIGAR. Cell 2006;126:30-2.
13. Vousden KH, Lane DP. p53 in health and disease. Nat Rev Mol Cell Biol 2007;8:275-83.
14. Coates PJ, Lorimore SA, Lindsay KJ, Wright EG. Tissue-specific p53 responses to ionizing radiation and their genetic modification: the key to tissue-specific tumour susceptibility?J Pathol 2003;201:377-88.
15. Fei P, Bernhard EJ, El-Deiry WS. Tissue-specific induction of p53 targets in vivo. Cancer Res 2002;62:7316-27. (Pubitemid 36025255)
16. Gottlieb E, Haffner R, King A, Asher G, Gruss P, Lonai P, et al. Transgenic mouse model for studying the transcriptional activity of the p53 protein: age- and tissue-dependent changes in radiation-induced activation during embryogenesis. EMBO J 1997;16:1381-90. (Pubitemid 27136103)
17. Komarova EA, Chernov MV, Franks R, Wang K, Armin G, Zelnick CR, et al. Transgenic mice with p53-responsive lacZ: p53 activity varies dramatically during normal development and determines radiation and drug sensitivity in vivo. EMBO J 1997;16:1391-400. (Pubitemid 27136104)
18. MacCallum DE, Hupp TR, Midgley CA, Stuart D, Campbell SJ, Harper A, et al. The p53 response to ionising radiation in adult and developing murine tissues. Oncogene 1996;13:2575-87. (Pubitemid 27046113)
19. Midgley CA, Owens B, Briscoe CV, Thomas DB, Lane DP, Hall PA. Coupling between gamma irradiation, p53 induction and the apoptotic response depends upon cell type in vivo. J Cell Sci 1995;108:1843-8.
20. Song S, Lambert PF. Different responses of epidermal and hair follicular cells to radiation correlate with distinct patterns of p53 and p21 induction. Am J Pathol 1999;155:1121-7. (Pubitemid 29488920)
21. Huper G, Marks JR. Isogenic normal basal and luminal mammary epithelial isolated by a novel method show a differential response to ionizing radiation. Cancer Res 2007;67:2990-3001. (Pubitemid 46724835)
22. Phillips TM, McBride WH, Pajonk F. The response of CD24(-/low)/ CD44+ breast cancer-initiating cells to radiation. J Natl Cancer Inst 2006;98:1777-85. (Pubitemid 46017929)
23. Ponten F, Lindman H, Bostrom A, Berne B, Bergh J. Induction of p53 expression in skin by radiotherapy and UV radiation: a randomized study. J Natl Cancer Inst 2001;93:128-33. (Pubitemid 32111990)
24. Simonsson M, Qvarnstrom F, Nyman J, Johansson KA, Garmo H, Turesson I. Low-dose hypersensitive gammaH2AX response and infrequent apoptosis in epidermis from radiotherapy patients. Radiother Oncol 2008;88:388-97.
25. Turesson I, Nyman J, Qvarnstrom F, Simonsson M, Book M, Hermansson I, et al. A low-dose hypersensitive keratinocyte loss in response to fractionated radiotherapy is associated with growth arrest and apoptosis. Radiother Oncol 2010;94:90-101.
26. Blance RN, Sims AH, Anderson E, Howell A, Clarke RB. Normal breast tissue implanted into athymic nude mice identifies biomarkers of the effects of human pregnancy levels of estrogen. Cancer Prev Res 2009;2:257-64.
27. Laidlaw IJ, Clarke RB, Howell A, Owen AW, Potten CS, Anderson E. The proliferation of normal human breast tissue implanted into athymic nude mice is stimulated by estrogen but not progesterone. Endocrinology 1995;136:164-71.
28. Nenutil R, Smardova J, Pavlova S, Hanzelkova Z, Muller P, Fabian P, et al. Discriminating functional and non-functional p53 in human tumours by p53 and MDM2 immunohistochemistry. J Pathol 2005;207:251-9. (Pubitemid 41556448)
29. Rogakou EP, Boon C, Redon C, Bonner WM. Megabase chromatin domains involved in DNA double-strand breaks in vivo. J Cell Biol 1999;146:905-16.
30. McManus MJ, Welsch CW. Hormone-induced ductal DNA synthesis of human breast tissues maintained in the athymic nude mouse. Cancer Res 1981;41:3300-5.
31. Kuperwasser C, Pinkas J, Hurlbut GD, Naber SP, Jerry DJ. Cytoplasmic sequestration and functional repression of p53 in the mammary epithelium is reversed by hormonal treatment. Cancer Res 2000;60:2723-9. (Pubitemid 30318250)
32. Minter LM, Dickinson ES, Naber SP, Jerry DJ. Epithelial cell cycling predicts p53 responsiveness to gamma-irradiation during post-natal mammary gland development. Development 2002;129: 2997-3008.
33. Sivaraman L, Conneely OM, Medina D, O'Malley BW. p53 is a potential mediator of pregnancy and hormone-induced resistance to mammary carcinogenesis. Proc Natl Acad Sci U S A 2001;98: 12379-84. (Pubitemid 33019954)
34. Poeze M, von Meyenfeldt MF, Peterse JL, George WD, de Jong JM, Jager JJ, et al. Increased proliferative activity and p53 expression in normal glandular breast tissue after radiation therapy. J Pathol 1998;185:32-7. (Pubitemid 28266714)
35. Gurley KE, Kemp CJ. Ataxia-telangiectasia mutated is not required for p53 induction and apoptosis in irradiated epithelial tissues. Mol Cancer Res 2007;5:1312-8.
36. Renwick A, Thompson D, Seal S, Kelly P, Chagtai T, Ahmed M, et al. ATM mutations that cause ataxia-telangiectasia are breast cancer susceptibility alleles. Nat Genet 2006;38:873-5.
37. Yap DB, Hsieh JK, Zhong S, Heath V, Gusterson B, Crook T, et al. Ser392 phosphorylation regulates the oncogenic function of mutant p53. Cancer Res 2004;64:4749-54. (Pubitemid 38924517)
38. Liefer KM, Koster MI, Wang XJ, Yang A, McKeon F, Roop DR. Down-regulation of p63 is required for epidermal UV-B-induced apoptosis. Cancer Res 2000;60:4016-20. (Pubitemid 30636575)
39. Westfall MD, Joyner AS, Barbieri CE, Livingstone M, Pietenpol JA. Ultraviolet radiation induces phosphorylation and ubiquitin-mediated degradation of DeltaNp63alpha. Cell Cycle 2005;4:710-6. (Pubitemid 41353857)
40. Craig AL, Holcakova J, Finlan LE, Nekulova M, Hrstka R, Gueven N, et al. DeltaNp63 transcriptionally regulates ATM to control p53 serine- 15 phosphorylation. Mol Cancer 2010;9:195.
41. Lin YL, Sengupta S, Gurdziel K, Bell GW, Jacks T, Flores ER. p63 and p73 transcriptionally regulate genes involved in DNA repair. PLoS Genet 2009;5:e1000680.
42. Castiglioni F, Terenziani M, Carcangiu ML, Miliano R, Aiello P, Bertola L, et al. Radiation effects on development of HER2-positive breast carcinomas. Clin Cancer Res 2007;13:46-51.
43. Finak G, Bertos N, Pepin F, Sadekova S, Souleimanova M, Zhao H, et al. Stromal gene expression predicts clinical outcome in breast cancer. Nat Med 2008;14:518-27.
44. Weigelt B, Bissell MJ. Unraveling the microenvironmental influences on the normal mammary gland and breast cancer. Semin Cancer Biol 2008;18:311-21.
45. Wiseman BS, Werb Z. Stromal effects on mammary gland development and breast cancer. Science 2002;296:1046-9. (Pubitemid 34517108)
46. Hede K. Fat may fuel breast cancer growth. J Natl Cancer Inst 2008;100:298-9.
47. Vona-Davis L, Rose DP. Adipokines as endocrine, paracrine, and autocrine factors in breast cancer risk and progression. Endocr Relat Cancer 2007;14:189-206. (Pubitemid 47242622)
48. Radisky DC, Hartmann LC. Mammary involution and breast cancer risk: transgenic models and clinical studies. J Mammary Gland Biol Neoplasia 2009;14:181-91.
49. Turashvili G, McKinney S, Martin L, Gelmon KA, Watson P, Boyd N, et al. Columnar cell lesions, mammographic density and breast cancer risk. Breast Cancer Res Treat 2009;115: 561-71.
50. Lopez E, Guerrero R, Nunez MI, del Moral R, Villalobos M, Martínez-Galán J, et al. Early and late skin reactions to radiotherapy for breast cancer and their correlation with radiation-induced DNA damage in lymphocytes. Breast Cancer Res 2005;7: R690-8.
51. Geara FB, Peters LJ, Ang KK, Wike JL, Sivon SS, Guttenberger R, et al. Intrinsic radiosensitivity of normal human fibroblasts and lymphocytes after high- and low-dose-rate irradiation. Cancer Res 1992;52:6348-52.
52. Slonina D, Klimek M, Szpytma T, Gasinska A. Comparison of the radiosensitivity of normal-tissue cells with normal-tissue reactions after radiotherapy. Int J Radiat Biol 2000;76:1255-64.
53. Blaydes JP, Craig AL, Wallace M, Ball HM, Traynor NJ, Gibbs NK, et al. Synergistic activation of p53-dependent transcription by two cooperating damage recognition pathways. Oncogene 2000;19: 3829-39. (Pubitemid 30658973)
54. Nylander K, Vojtesek B, Nenutil R, Lindgren B, Roos G, Zhanxiang W, et al. Differential expression of p63 isoforms in normal tissues and neoplastic cells. J Pathol 2002;198:417-27. (Pubitemid 35446994)